EarlyScreenDx is pioneering a new generation of point-of-care cancer detection kits powered by proprietary biomarker technology that identifies cancerous and precancerous tissue with a simple colorimetric reaction.
EarlyScreenDx is a diagnostics company built on one conviction: cancer detected early saves lives. We are translating cutting-edge biomarker science into accessible, affordable screening tools that can reach patients before symptoms appear.
Founded by a team spanning oncology, molecular biology, and healthcare operations, we are developing our flagship colon cancer detection kit in collaboration with leading Indian biotech partners, with breast and lung cancer screening kits already in the roadmap.
To make cancer screening as routine as a blood pressure check, empowering millions to catch the disease at its most treatable stage.
We combine proprietary biomarker discovery with simple colorimetric chemistry, enabling results that are readable without complex laboratory equipment.
We work with established Indian diagnostic manufacturing partners to accelerate kit scale-up and quality validation.
Our patented platform detects a unique biomarker expressed in cancerous and precancerous tissue and turns it into colour you can see.
A proprietary biomarker expressed specifically in cancerous and precancerous colorectal tissue is targeted by our detection system. The biomarker is absent in healthy tissue, providing high specificity.
Patients provide a simple, non-invasive sample at the point of care using our collection kit. No bowel prep, no sedation, and no complex laboratory infrastructure required.
When the sample contacts our proprietary reagents, a colorimetric reaction occurs exclusively in the presence of the cancer biomarker, producing a visible colour change that indicates a positive result.
Our intellectual property covers both the biomarker target and the reagent system, creating a defensible, first-mover advantage across multiple cancer types.
Positive results are followed by confirmatory clinical diagnostics. Our system is designed as a population-level first screen, safe, scalable, and actionable.
Live Reaction Demo
Sample
Reagent
Result
Colour change indicates biomarker presence
Our rectal mucus assay is designed for real-world clinical settings — simple sample collection, no laboratory equipment, and an unambiguous colorimetric readout that guides next steps immediately.
Our lead product. Kit validation underway with our manufacturing partners. Targeting launch as India's first point-of-care colorectal cancer screening kit.
Biomarker candidates identified. Early feasibility studies planned. Leveraging platform reagent chemistry developed for colorectal indication.
Stage-gate planned post breast-cancer feasibility. Target to build a comprehensive early detection portfolio addressing India's top cancer burden.
Every existing screening option forces a trade-off — accuracy, cost, or reach. EarlyScreenDx is built to deliver all three at the point of care.
Comparator figures reflect published ranges for each modality. EarlyScreenDx sensitivity reflects independent published studies across 9,000+ patients.
Our founders bring together expertise in molecular biology, oncology, and business strategy to translate a breakthrough technology into a scalable healthcare solution.
Visionary leader driving EarlyScreenDx's strategic direction, investor relations, and commercial growth. Committed to making early cancer detection accessible across India and beyond.
Oversees organisational leadership and partnership development. Brings deep expertise in healthcare operations and stakeholder management to scale the company's mission.
Drives execution across product development, manufacturing partnerships, and regulatory pathways. Ensures that R&D breakthroughs translate seamlessly into market-ready products.
The scientific architect of EarlyScreenDx's biomarker platform. Leads the discovery, validation, and IP development of the proprietary detection technology underpinning our entire product portfolio.
Leads day-to-day operational execution across research, manufacturing, and logistics. Brings scientific rigour and operational discipline to ensure seamless delivery from lab to market.
Drives the translation of EarlyScreenDx's core biomarker science from bench to clinical application. Brings rigorous expertise in molecular diagnostics and cancer biology to validate and optimise the proprietary detection platform for real-world deployment.
Our advisory board brings decades of experience in drug discovery, venture building, and cancer biology from leading global institutions.
Director of Cardiovascular at Flagship Pioneering. Nearly a decade of drug discovery experience across oncology, cardiovascular, and infectious diseases. Co-inventor of Camzyos, the first-in-class FDA-approved therapy for hypertrophic cardiomyopathy. Co-founder of Kainomyx Inc. PhD from TIFR India; postdoctoral fellow at Stanford University. Published in Science, Nature, and PNAS.
We welcome conversations with clinicians, investors, healthcare systems, and research institutions who share our vision for accessible early cancer detection.
Ready to connect?
Fill out our contact form and a member of the EarlyScreenDx team will get back to you shortly.
Get In Touch ↗